Top Stories of 2022
Top Stories of 2022
Revisit some of Gladstone’s most important stories from the past year
Gladstone Experts Cardiovascular Disease Data Science and Biotechnology Genomic Immunology Neurological Disease VirologyGladstone NOW: The Campaign Join Us on the Journey ✕
31 - 45 of 228 Results Clear All
Revisit some of Gladstone’s most important stories from the past year
Gladstone Experts Cardiovascular Disease Data Science and Biotechnology Genomic Immunology Neurological Disease VirologySan Francisco Chronicle—Although requirements for mask wearing and social distancing have eased around the country, a third winter of the pandemic is looming. Gladstone Senior Investigator Warner Greene recommends paying attention to local trends in case numbers to decide which COVID-19 precautions to take.
Gladstone Experts COVID-19 Virology Greene LabSan Francisco Chronicle—Senior Investigator Warner Greene, MD, PhD, shares his views on the likelihood of a new COVID surge this winter.
Gladstone Experts COVID-19 Virology Greene LabInvisishield Technologies—Gladstone Senior Investigator Warner Greene has been appointed President and Chief Scientific Officer of Invisihield Technologies. Invisishield is focused on developing intranasal preventatives for respiratory viruses, including SARS-CoV-2.
Gladstone Experts COVID-19 Virology Greene LabABC7 News—Senior Investigator Nadia Roan, PhD, says that a winter surge of infections from the highly transmissible new variants of SARS-CoV-2 currently emerging in the US is likely, but it remains unclear how bad it will be.
Gladstone Experts COVID-19 Virology Roan LabSan Francisco Chronicle—The new bivalent COVID-19 booster shots are recommended for individuals age 5 and up who are at least two months past their last vaccine dose. Gladstone Investigator Nadia Roan explains that the bivalent boosters greatly increase the levels of antibodies that can prevent the Omicron variant from infecting cells.
Gladstone Experts COVID-19 Virology Roan LabSan Francisco Chronicle—New COVID-19 booster shots targeting both the ancestral virus and omicron strains are now available. Gladstone Investigator Nadia Roan weighs in on when people should get the jab, based on the timing of their last dose and whether they’ve been recently infected.
Gladstone Experts COVID-19 Virology Roan LabThe single-dose, intranasal treatment also reduces symptoms of multiple variants of the SARS-CoV-2 virus
News Release Research (Publication) COVID-19 Center for Cell Circuitry Virology Weinberger Lab ChaturvediSan Francisco Chronicle—Senior Investigator Warner Greene, MD, PhD, says that it makes more sense to boost immunity with the newly approved bivalent vaccines targeting Omicron than with vaccines that aim at long-extinct variants of the coronavirus.
Gladstone Experts COVID-19 Center for HIV Cure Research Virology Greene LabGladstone scientists address the basics—and dispel misconceptions—about MPXV
Gladstone Experts MPXV VirologyABC7 News—The federal government plans to roll out a new vaccine against the BA.5 Omicron variant now predominant in the US early this fall. Senior Investigator Warner Greene, MD, PhD, says that you might want to hold off for your next booster shot until you can get this new vaccine, which will offer better protection against currently circulating variants.
Gladstone Experts COVID-19 Center for HIV Cure Research Virology Greene LabThe Daily Californian—Senior Investigator Melanie Ott, MD, PhD, and collaborator Abdullah Syed, PhD, a postdoctoral fellow in the laboratory of Senior Investigator Jennifer Doudna, explain how they discovered that antibodies against early versions of the SARS-CoV-2 virus do not protect well against the now widespread and highly contagious Omicron variant, and recommend masking to avoid new infections.
Gladstone Experts COVID-19 Data Science and Biotechnology Virology Doudna Lab Ott LabResearchers used virus-like particles to identify which mutations of the Omicron SARS-CoV-2 virus make it more effective at infecting cells and escaping antibodies
News Release Research (Publication) COVID-19 Virology Doudna Lab Ott LabGladstone researchers find new evidence against using BET inhibitors to treat COVID-19
News Release Research (Publication) COVID-19 Virology Ott LabNIH Director’s Blog—Recent work from the team of Gladstone Associate Investigator Nadia Roan, PhD, and their colleagues at The Wistar Institute is featured in this week’s NIH Director’s Blog. The work uncovers intriguing evidence for the role of sugars at the surface of immune cells in HIV infection.
Gladstone Experts HIV/AIDS Virology Roan Lab